Article Details

China's NMPA Approves Isatuximab Plus VRd for Newly Diagnosed, Transplant-Ineligible Myeloma

Retrieved on: 2025-01-31 22:36:35

Tags for this article:

Click the tags to see associated articles and topics

China's NMPA Approves Isatuximab Plus VRd for Newly Diagnosed, Transplant-Ineligible Myeloma. View article details on hiswai:

Excerpt

At least 2 prior lines of therapy were required, and 1 line needed to include an anti-CD20 monoclonal antibody and an alkylating agent; however ...

Article found on: www.onclive.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up